Role of Immunotherapy in Triple-Negative Breast Cancer

被引：391

作者：

Keenan, Tanya E. ^{[1
,2
]}

Tolaney, Sara M. ^{[1
,2
]}

机构：

[1] Dana Farber Canc Inst, Dept Med Oncol, 450 Brookline Ave, Boston, MA 02115 USA

[2] Harvard Med Sch, Boston, MA 02115 USA

来源：

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK | 2020年 / 18卷 / 04期

关键词：

PHASE-II; T-CELLS; PEMBROLIZUMAB; CHEMOTHERAPY; EFFICACY; PD-L1; BLOCKADE; RECEPTOR; SAFETY; LYMPHOCYTES;

D O I：

10.6004/jnccn.2020.7554

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Immune checkpoint inhibitors (ICIs) have led to durable clinical remissions in many metastatic cancers. However, the single-agent efficacy of ICIs in breast cancer is low, including in triple-negative breast cancer (TNBC), which has several key characteristics that enhance ICI responses. Strategies to improve anticancer immune responses in TNBC are urgently needed to extend survival for patients with metastatic disease. This review presents ICI monotherapy response rates and discusses combination strategies with chemotherapy, targeted therapies, and novel immunotherapies. It concludes with a summary of immunotherapy biomarkers in TNBC and a call to action for future directions of research critical to advancing the efficacy of immunotherapy for patients with TNBC.

引用

页码：479 / 489

页数：11

共 83 条

[1]

Adams S, 2019, ANN ONCOL, V30, P405, DOI [10.1093/annonc/mdy518, 10.1093/annonc/mdy517]

[2] Atezolizumab Plus nab-Paclitaxel in the Treatment of Metastatic Triple-Negative Breast Cancer With 2-Year Survival Follow-up A Phase 1b Clinical Trial [J].

Adams, Sylvia ;

Diamond, Jennifer R. ;

Hamilton, Erika ;

Pohlmann, Paula R. ;

Tolaney, Sara M. ;

Chang, Ching-Wei ;

Zhang, Wei ;

Iizuka, Koho ;

Foster, Paul G. ;

Molinero, Luciana ;

Funke, Roel ;

Powderly, John .

JAMA ONCOLOGY, 2019, 5 (03) :334-342

[3]

[Anonymous], 2019, 2019 SAN ANT BREAST

[4]

[Anonymous], 2019, J CLIN ONCOL S

[5]

[Anonymous], 2019, CANC RES S

[6]

[Anonymous], CANC RES S

[7] Prevalence and mutational determinants of high tumor mutation burden in breast cancer [J].

Barroso-Sousa, R. ;

Jain, E. ;

Cohen, O. ;

Kim, D. ;

Buendia-Buendia, J. ;

Winer, E. ;

Lin, N. ;

Tolaney, S. M. ;

Wagle, N. .

ANNALS OF ONCOLOGY, 2020, 31 (03) :387-394

[8] Tumor Mutational Burden and PTEN Alterations as Molecular Correlates of Response to PD-1/L1 Blockade in Metastatic Triple-Negative Breast Cancer [J].

Barroso-Sousa, Romualdo ;

Keenan, Tanya E. ;

Pernas, Sonia ;

Exman, Pedro ;

Jain, Esha ;

Garrido-Castro, Ana C. ;

Hughes, Melissa ;

Bychkovsky, Brittany ;

Umeton, Renato ;

Files, Janet L. ;

Lindeman, Neal I. ;

MacConaill, Laura E. ;

Hodi, F. Stephen ;

Krop, Ian E. ;

Dillon, Deborah ;

Winer, Eric P. ;

Wagle, Nikhil ;

Lin, Nancy U. ;

Mittendorf, Elizabeth A. ;

Van Allen, Eliezer M. ;

Tolaney, Sara M. .

CLINICAL CANCER RESEARCH, 2020, 26 (11) :2565-2572

[9] Determinants of high tumor mutational burden (TMB) and mutational signatures in breast cancer [J].

Barroso-Sousa, Romualdo ;

Jain, Esha ;

Kim, Dewey ;

Partridge, Ann H. ;

Cohen, Ofir ;

Wagle, Nikhil .

JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)

[10] A First-in-Human Study and Biomarker Analysis of NKTR-214, a Novel 1L2Rβγ-Biased Cytokine, in Patients with Advanced or Metastatic Solid Tumors [J].

Bentebibel, Salah-Eddine ;

Hurwitz, Michael E. ;

Bernatchez, Chantale ;

Haymaker, Cara ;

Hudgens, Courtney W. ;

Kluger, Harriet M. ;

Tetzlaff, Michael T. ;

Tagliaferri, Mary A. ;

Zalevsky, Jonathan ;

Hoch, Ute ;

Fanton, Christie ;

Aung, Sandra ;

Hwu, Patrick ;

Curti, Brendan D. ;

Tannir, Nizar M. ;

Sznol, Mario ;

Diab, Adi .

CANCER DISCOVERY, 2019, 9 (06) :711-721

← 1 2 3 4 5 6 7 8 9 →